Athira Pharma (ATHA) Competitors $0.61 +0.18 (+42.26%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATHA vs. SQZ, PASG, EPRX, GANX, ENTX, RAPT, CTXR, CNTB, VRCA, and VNRXShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include SQZ Biotechnologies (SQZ), Passage Bio (PASG), Eupraxia Pharmaceuticals (EPRX), Gain Therapeutics (GANX), Entera Bio (ENTX), RAPT Therapeutics (RAPT), Citius Pharmaceuticals (CTXR), Connect Biopharma (CNTB), Verrica Pharmaceuticals (VRCA), and VolitionRx (VNRX). These companies are all part of the "medical" sector. Athira Pharma vs. SQZ Biotechnologies Passage Bio Eupraxia Pharmaceuticals Gain Therapeutics Entera Bio RAPT Therapeutics Citius Pharmaceuticals Connect Biopharma Verrica Pharmaceuticals VolitionRx SQZ Biotechnologies (NYSE:SQZ) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Which has more volatility and risk, SQZ or ATHA? SQZ Biotechnologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Does the MarketBeat Community prefer SQZ or ATHA? Athira Pharma received 10 more outperform votes than SQZ Biotechnologies when rated by MarketBeat users. However, 66.67% of users gave SQZ Biotechnologies an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote. CompanyUnderperformOutperformSQZ BiotechnologiesOutperform Votes1066.67% Underperform Votes533.33% Athira PharmaOutperform Votes2054.05% Underperform Votes1745.95% Is SQZ or ATHA more profitable? Athira Pharma has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. Athira Pharma's return on equity of -95.53% beat SQZ Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets SQZ Biotechnologies-369.96% -119.83% -59.90% Athira Pharma N/A -95.53%-76.96% Do institutionals and insiders believe in SQZ or ATHA? 38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Comparatively, 19.8% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer SQZ or ATHA? In the previous week, SQZ Biotechnologies' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score. Company Overall Sentiment SQZ Biotechnologies Neutral Athira Pharma Neutral Which has preferable earnings & valuation, SQZ or ATHA? SQZ Biotechnologies has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSQZ Biotechnologies$18.16M0.04-$79.46M-$2.61-0.01Athira PharmaN/AN/A-$117.67M-$2.97-0.20 Do analysts rate SQZ or ATHA? Athira Pharma has a consensus target price of $13.83, indicating a potential upside of 2,183.11%. Given Athira Pharma's higher probable upside, analysts clearly believe Athira Pharma is more favorable than SQZ Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAthira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAthira Pharma beats SQZ Biotechnologies on 7 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.29M$3.14B$5.50B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.2012.03116.1015.23Price / SalesN/A400.761,496.2597.74Price / CashN/A149.0039.7434.10Price / Book0.184.024.775.07Net Income-$117.67M-$42.25M$119.06M$225.46M7 Day Performance29.52%8.04%0.80%0.37%1 Month Performance37.21%8.69%5.65%3.57%1 Year Performance-63.50%32.09%36.75%29.43% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma2.5581 of 5 stars$0.61+42.3%$13.83+2,183.1%-65.4%$23.29MN/A-0.2040Gap UpHigh Trading VolumeSQZSQZ BiotechnologiesN/A$0.44+61.1%N/AN/A$12.83M$18.16M-0.171,620Gap UpHigh Trading VolumePASGPassage Bio2.6315 of 5 stars$0.60-6.4%$8.33+1,281.1%-2.3%$37.19MN/A-0.45130Gap DownEPRXEupraxia PharmaceuticalsN/A$2.58+3.6%N/AN/A$70.38MN/A-3.1929News CoverageGap UpGANXGain Therapeutics3.7516 of 5 stars$2.65-1.1%$7.33+176.7%-17.1%$67.65M$50,000.00-2.0420Short Interest ↓ENTXEntera Bio2.8872 of 5 stars$1.88+3.3%$10.00+431.9%+170.4%$67.27M$130,000.00-7.2320Short Interest ↓Gap UpRAPTRAPT Therapeutics3.6665 of 5 stars$1.89+6.8%$18.17+861.2%-84.3%$65.97M$1.53M-0.6180News CoveragePositive NewsCTXRCitius Pharmaceuticals2.301 of 5 stars$0.36+5.2%$4.00+998.9%-53.4%$65.77MN/A-1.5220Positive NewsCNTBConnect Biopharma3.1615 of 5 stars$1.19-2.9%$8.00+575.1%-33.3%$65.30M$24.12M0.00110Gap DownVRCAVerrica Pharmaceuticals4.1911 of 5 stars$1.51+0.7%$11.40+655.0%-58.1%$64.43M$5.12M-0.8040Gap UpVNRXVolitionRx1.8302 of 5 stars$0.70-4.7%$2.50+259.5%-18.3%$64.05M$770,000.00-1.7480News CoverageGap Up Related Companies and Tools Related Companies SQZ Competitors PASG Competitors EPRX Competitors GANX Competitors ENTX Competitors RAPT Competitors CTXR Competitors CNTB Competitors VRCA Competitors VNRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATHA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
